期刊
JOURNAL OF INFECTIOUS DISEASES
卷 203, 期 4, 页码 473-478出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiq077
关键词
-
资金
- Mutua Madrilena del Automovil, STREP (UE) Life sciences [FIS PS09/01297, FIPSE 36750/08, SAF2008-04395, SAF 05/05566, FIPSE 36536/05, FIS 040503, FIS 070291, FIS 03/0072]
- IDIBAPS, Barcelona, Spain
- Fundacio Privada Clinic per a la Recerca Biomedica in collaboration with the Spanish Health Department [FIS 03/0072]
- National Cancer Institute, National Institutes of Health [HHSN261200800001E]
- Spanish Ministry of Health
- Abbott Laboratories
- Boehringer Ingelheim
- Bristol Myers Squibb
- GlaxoSmithKline
- Merck Sharp
- Dohme
- Roche
- ICREA Funding Source: Custom
A double-blinded, controlled study of vaccination of untreated patients with chronic human immunodeficiency virus type 1 (HIV-1) infection with 3 doses of autologous monocyte-derived dendritic cells (MD-DCs) pulsed with heat inactivated autologous HIV-1 was performed. Therapeutic vaccinations were feasible, safe, and well tolerated. At week 24 after first vaccination (primary end point), a modest significant decrease in plasma viral load was observed in vaccine recipients, compared with control subjects (P = .03). In addition, the change in plasma viral load after vaccination tended to be inversely associated with the increase in HIV-specific T cell responses in vaccinated patients but tended to be directly correlated with HIV-specific T cell responses in control subjects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据